M. Amann

发表

Fibroblast activation protein-targeted-4-1BB ligand agonist amplifies effector functions of intratumoral T cells in human cancer

C. Klein, K. Mertz, R. Rosenberg, 2020, Journal for ImmunoTherapy of Cancer.

Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy

C. Klein, C. Whitlow, H. Stahlberg, 2019, Science Translational Medicine.

Therapeutic window of an EpCAM/CD3-specific BiTE antibody in mice is determined by a subpopulation of EpCAM-expressing lymphocytes that is absent in humans

M. Friedrich, R. Kischel, P. Kufer, 2008, Cancer Immunology, Immunotherapy.

Elective nodal irradiation mitigates local and systemic immunity generated by combination radiation and immunotherapy in head and neck tumors

S. Karam, S. Dow, Molishree Joshi, 2022, Nature Communications.

The in vitro hepatic metabolism of ABT-418, a cholinergic channel activator, in rats, dogs, cynomolgus monkeys, and humans.

A. D. Rodrigues, J. Sullivan, D. Garvey, 1994, Drug metabolism and disposition: the biological fate of chemicals.

CEA/CD3 bispecific antibody MEDI-565/AMG 211 activation of T cells and subsequent killing of human tumors is independent of mutations commonly found in colorectal adenocarcinomas

S. Coats, P. Baeuerle, S. Hammond, 2014, mAbs.

CD25-Treg-depleting antibodies preserving IL-2 signaling on effector T cells enhance effector activation and antitumor immunity

A. Akarca, T. Marafioti, S. Quezada, 2020, Nature Cancer.

Therapeutic window of MuS110, a single-chain antibody construct bispecific for murine EpCAM and murine CD3.

R. Kischel, P. Kufer, R. Lutterbuese, 2008, Cancer research.

Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma

J. San Miguel, J. Martinez-Climent, F. Prósper, 2023, Nature Medicine.

Antitumor Activity of an EpCAM/CD3-bispecific BiTE Antibody During Long-term Treatment of Mice in the Absence of T-cell Anergy and Sustained Cytokine Release

M. Friedrich, R. Kischel, P. Kufer, 2009, Journal of immunotherapy.

Therapeutic Window of MuS 110 , a Single-Chain Antibody Construct Bispecific for Murine EpCAM and Murine CD 3

R. Kischel, P. Kufer, R. Lutterbuese, 2007 .

Simultaneous targeting of PD-1 and IL-2Rβγ with radiation therapy inhibits pancreatic cancer growth and metastasis.

S. Karam, Molishree Joshi, Nicholas A. Olimpo, 2023, Cancer cell.

Abstract 3634: A novel tumor-targeted 4-1BB agonist and its combination with T-cell bispecific antibodies: an off-the-shelf cancer immunotherapy alternative to CAR T-cells

C. Klein, M. Bacac, S. Colombetti, 2017 .

The PET-Tracer 89Zr-Df-IAB22M2C Enables Monitoring of Intratumoral CD8 T-cell Infiltrates in Tumor-Bearing Humanized Mice after T-cell Bispecific Antibody Treatment

C. Klein, T. Nayak, M. Bacac, 2020, Cancer Research.

EnablesMonitoring of Intratumoral CD8 T-cell Infiltrates in Tumor-Bearing Humanized Mice after T-cell Bispecific Antibody Treatment

C. Klein, T. Nayak, M. Bacac, 2020 .

Selective targeting of IL2Rβγ combined with radiotherapy triggers CD8- and NK-mediated immunity, abrogating metastasis in HNSCC

S. Karam, P. Umaña, Christian Klein, 2023, Cell reports. Medicine.

CD25 targeting with the afucosylated human IgG1 antibody RG6292 eliminates regulatory T cells and CD25+ blasts in acute myeloid leukemia

C. Klein, K. Korfi, V. Karanikas, 2023, Frontiers in Oncology.

Optimizing Early Clinical Investigations in Cancer Immunotherapy: The Translational Journey of RG6292, a Novel, Selective Treg-Depleting Antibody.

Laurène Pousse, Nicole Justies, Estelle Marrer-Berger, 2024, Clinical pharmacology and therapeutics.